https://aspenneuroscience.com/aspen-neuroscience-announces-reconstitution-of-the-board-of-directors/2022-04-25T12:25:30-07:00https://aspenneuroscience.com/regulatory-affairs-expert-ana-sousa-joins-aspen-neuroscience/2022-09-01T16:19:34-07:00https://aspenneuroscience.com/caryn-peterson-joins-aspen-nueroscience-board-of-directors/2022-04-25T12:08:54-07:00https://aspenneuroscience.com/an-autologous-stem-cell-based-therapy-for-parkinsons-disease/2022-04-21T13:23:00-07:00https://aspenneuroscience.com/aspen-neuroscience-gets-70-million-series-a-funding-round/2022-04-21T13:24:29-07:00https://aspenneuroscience.com/aspen-neuroscience-announces-appointment-of-damien-mcdevitt-phd-as-president-and-chief-executive-officer/2022-05-03T07:57:49-07:00https://aspenneuroscience.com/70-million-raised-for-neuron-replacement-therapy-techniques-to-treat-parkinsons/2022-04-21T13:25:25-07:00https://aspenneuroscience.com/possible-parkinsons-stem-cell-treatment-in-san-diego-6-5-million-and-loads-of-media-coverage/2022-04-21T13:27:34-07:00https://aspenneuroscience.com/pioneering-cell-therapy-for-parkinsons-disease-gains-funding-boost/2022-04-21T14:35:20-07:00https://aspenneuroscience.com/aspen-neuroscience-announces-management-transition/2022-04-25T14:58:41-07:00https://aspenneuroscience.com/how-research-in-space-can-launch-girls-ideas/2022-04-21T14:40:45-07:00https://aspenneuroscience.com/the-first-3d-models-of-parkinsons-ms-are-headed-into-space/2022-04-21T14:49:42-07:00https://aspenneuroscience.com/jeanne-loring-named-stem-cell-pioneer-of-the-year-in-inaugural-xconomy-awards/2022-04-21T14:52:21-07:00https://aspenneuroscience.com/genomics-for-stem-cell-based-therapies/2026-06-15T19:15:59-07:00https://aspenneuroscience.com/the-new-news-in-stem-cell-research/2026-06-15T19:14:56-07:00https://aspenneuroscience.com/scientific-leader-xiaokui-zhang-phd-joins-aspen-neuroscience/2022-05-08T20:43:53-07:00https://aspenneuroscience.com/industry-veteran-kameel-farag-joins-aspen-neuroscience-as-chief-financial-officer/2025-05-07T09:05:10-07:00https://aspenneuroscience.com/aspen-neuroscience-announces-70-million-series-a-financing-led-by-orbimed-to-advance-development-of-the-first-autologous-neuron-replacement-therapy-to-treat-parkinson-disease/2022-04-22T08:35:57-07:00https://aspenneuroscience.com/aspen-neuroscience-launches-with-6-5-million-seed-funding-to-advance-first-of-its-kind-personalized-cell-therapy-for-parkinsons-disease/2022-04-25T12:40:12-07:00https://aspenneuroscience.com/first-in-kind-human-3-dimensional-models-of-parkinsons-disease-and-progressive-multiple-sclerosis-launching-to-the-international-space-station/2022-04-25T12:43:20-07:00https://aspenneuroscience.com/aspen-neuroscience-launches-first-patient-screening-study-forplanned-clinical-trial-of-personalized-cell-replacement-in-parkinsons-disease/2022-04-29T19:14:14-07:00https://aspenneuroscience.com/aspen-neuroscience-to-present-at-2020-virtual-cell-gene-meeting-on-the-mesa/2022-04-25T12:17:35-07:00https://aspenneuroscience.com/aspen-neuroscience-announces-board-of-directors-and-scientific-advisory-board/2022-04-25T12:36:23-07:00https://aspenneuroscience.com/aspen-neuroscience-announces-series-b-financing/2026-01-09T11:54:30-08:00https://aspenneuroscience.com/neuritest-presented-publicly-for-the-first-time-at-the-international-society-for-stem-cell-research-annual-meeting/2022-06-22T15:34:31-07:00https://aspenneuroscience.com/aspen-neuroscience-collects-large-series-b-to-compete-against-bayers-parkinsons-cell-therapy/2022-08-12T14:04:14-07:00https://aspenneuroscience.com/aspen-neuroscience-pursues-autologous-cell-therapies-for-parkinsons-with-147-5m-series-b/2022-10-11T10:53:06-07:00https://aspenneuroscience.com/dr-xiaokui-zhang-to-present-aspen-neuroscience-inc-at-2022-cell-gene-on-the-mesa/2022-10-12T14:38:43-07:00https://aspenneuroscience.com/cmc-expert-kim-raineri-joins-aspen-neuroscience-as-chief-technology-officer/2022-11-04T08:35:17-07:00https://aspenneuroscience.com/aspen-neurosciences-david-tastad-phd-presented-at-the-annual-society-for-neuroscience-meeting/2022-11-15T12:42:42-08:00https://aspenneuroscience.com/thorsten-gorba-xiaokui-zhang-o-present-ipsc-derived-cell-therapies-summit/2022-12-09T09:52:05-08:00https://aspenneuroscience.com/aspen-neuroscience-will-present-at-the-annual-ipsc-derived-cell-therapies-summit/2022-12-07T16:06:57-08:00https://aspenneuroscience.com/aspen-neuroscience-inks-40-million-debt-deal-with-silicon-valley-bank/2025-05-05T10:32:52-07:00https://aspenneuroscience.com/aspen-neuroscience-selected-as-a-finalist-for-the-phacilitate-biotech-innovation-award/2023-01-24T12:32:25-08:00https://aspenneuroscience.com/kim-raineri-and-andres-bratt-leal-phd-presented-at-phacilitate-advanced-therapies-week/2023-01-24T12:44:36-08:00https://aspenneuroscience.com/damien-mcdevitt-phd-featured-in-biocoms-article-a-look-at-the-year-ahead-for-life-sciences/2023-01-24T12:46:42-08:00https://aspenneuroscience.com/aspen-neuroscience-featured-in-wall-street-journal/2023-03-24T14:47:10-07:00https://aspenneuroscience.com/chief-scientific-officer-xiaokui-zhang-profiled-in-insights-care-magazine/2023-04-17T17:10:50-07:00https://aspenneuroscience.com/dr-andres-bratt-leal-to-present-at-the-2023-international-society-for-stem-cell-research-annual-meeting-focus-sessions/2026-02-06T13:18:44-08:00https://aspenneuroscience.com/dr-andres-bratt-leal-to-present-preclinical-safety-and-efficacy-data-for-anpd001-at-the-2023-world-parkinson-congress-in-barcelona/2026-02-06T13:18:05-08:00https://aspenneuroscience.com/preclinical-safety-and-efficacy-data-for-anpd001-presented-by-dr-andres-bratt-leal-at-2023-world-parkinson-congress-in-barcelona/2023-08-08T08:42:41-07:00https://aspenneuroscience.com/aspen-neuroscience-announces-fda-clearance-of-investigational-new-drug-application-for-anpd001-autologous-cell-therapy-for-the-treatment-of-parkinsons-disease/2026-01-09T11:52:41-08:00https://aspenneuroscience.com/aspen-neuroscience-to-partner-with-rune-labs-and-emerald-innovations-to-incorporate-both-active-and-passive-digital-health-monitoring-in-trial-ready-cohort-screening-study/2026-01-09T11:52:17-08:00https://aspenneuroscience.com/aspen-neuroscience-to-present-at-2023-cell-gene-meeting-on-the-mesa/2023-10-09T07:44:53-07:00https://aspenneuroscience.com/fda-grants-fast-track-designation-to-anpd001-autologous-investigational-cell-therapy-for-the-treatment-of-parkinsons-disease/2023-10-19T08:56:37-07:00https://aspenneuroscience.com/dr-andres-bratt-leal-receives-2023-biocom-california-life-science-catalyst-award/2023-11-21T08:07:06-08:00https://aspenneuroscience.com/aspen-neuroscience-to-present-at-future-of-parkinsons-disease-conference/2023-11-30T09:44:11-08:00https://aspenneuroscience.com/aspen-neuroscience-appoints-ana-sousa-chief-regulatory-officer/2025-10-19T11:21:14-07:00https://aspenneuroscience.com/dr-lisa-johnson-pratt-joins-aspen-neuroscience-as-senior-vice-president-therapeutic-program-lead/2024-02-14T08:17:00-08:00https://aspenneuroscience.com/aspen-neuroscience-announces-first-patient-dosed-in-first-in-human-phase-1-2a-clinical-trial-of-autologous-neuronal-cell-replacement-therapy-for-parkinsons-disease/2026-01-09T11:51:45-08:00https://aspenneuroscience.com/aspen-neuroscience-receives-clin2-grant-for-anpd001-from-california-institute-for-regenerative-medicine-cirm/2026-01-09T11:50:31-08:00https://aspenneuroscience.com/aspen-neuroscience-to-present-at-international-society-for-cell-gene-therapy-isct-annual-meeting/2026-01-09T11:50:01-08:00https://aspenneuroscience.com/parkinsons-disease-clinical-trial-uses-intraoperative-mri-to-guide-precision-implantation-of-patients-own-autologous-replacement-neurons/2026-01-09T11:49:31-08:00https://aspenneuroscience.com/aspen-neuroscience-to-present-at-stifel-2024-cell-therapy-forum-july-9/2024-07-08T08:47:45-07:00https://aspenneuroscience.com/aspen-neuroscience-to-present-at-2024-raymond-james-biotech-private-company-showcase-july-18/2024-07-17T08:28:58-07:00https://aspenneuroscience.com/study-of-anpd001-autologous-neuronal-cell-replacement-treatment-approach-published-in-journal-of-neurosurgery/2024-07-29T08:39:49-07:00https://aspenneuroscience.com/aspen-neuroscience-announces-dosing-completion-of-first-cohort-in-aspiro-phase-1-2a-trial-for-parkinsons-disease/2026-02-06T13:16:58-08:00https://aspenneuroscience.com/aspen-neuroscience-chief-financial-officer-kameel-farag-to-present-at-upcoming-investor-conferences/2026-02-03T11:31:04-08:00https://aspenneuroscience.com/aspen-neuroscience-announces-expansion-of-autologous-cell-therapy-manufacturing-in-san-diego/2026-01-09T11:48:25-08:00https://aspenneuroscience.com/aspen-neuroscience-to-showcase-advances-in-autologous-cell-therapy-development-at-2024-cell-gene-meeting-on-the-mesa/2026-02-03T11:22:22-08:00https://aspenneuroscience.com/aspen-neuroscience-announces-collaboration-and-license-agreement-with-cell-x-technologies/2024-10-08T09:57:27-07:00https://aspenneuroscience.com/endpoints-news-honors-aspen-neuroscience-co-founder-dr-jeanne-loring-in-20-women-breaking-new-ground/2024-10-08T09:01:12-07:00https://aspenneuroscience.com/aspen-neuroscience-chief-financial-officer-kameel-farag-to-present-at-ubs-global-healthcare-conference/2025-05-07T09:04:43-07:00https://aspenneuroscience.com/ceo-damien-mcdevitt-named-in-san-diego-business-journals-500-most-influential-people-in-san-diego/2025-04-01T12:26:53-07:00https://aspenneuroscience.com/aspen-neuroscience-advances-the-automated-production-of-personalized-autologous-cell-therapy-for-parkinsons-disease/2026-01-09T11:47:05-08:00https://aspenneuroscience.com/aspen-neuroscience-announces-completion-of-first-and-second-cohorts-in-aspiro-phase-1-2a-trial-for-parkinsons-disease/2026-01-09T06:36:11-08:00https://aspenneuroscience.com/the-aspen-neuroscience-team-is-proud-to-sponsor-and-participate-in-the-annual-step-by-step-5k-hosted-by-the-parkinsons-association-of-san-diego-pasd-on-saturday-april-5th/2025-04-01T12:25:46-07:00https://aspenneuroscience.com/dalen-meeter-joins-aspen-neuroscience-as-chief-financial-officer/2026-01-09T07:43:48-08:00https://aspenneuroscience.com/aspen-neuroscience-to-present-at-the-international-society-for-gene-cell-therapy-isct-annual-meeting/2026-01-09T07:42:29-08:00https://aspenneuroscience.com/aspen-neuroscience-announces-6-month-aspiro-phase-1-2a-clinical-trial-results-of-personalized-cell-therapy-for-parkinsons-disease/2025-05-10T12:28:29-07:00https://aspenneuroscience.com/aspen-neuroscience-to-present-at-american-society-of-gene-cell-therapy-asgct-annual-meeting/2026-01-09T11:46:39-08:00https://aspenneuroscience.com/aspen-neuroscience-to-present-at-the-international-society-for-stem-cell-research-isscr-2025-annual-meeting/2026-01-09T11:45:24-08:00https://aspenneuroscience.com/aspen-neuroscience-initiates-cohort-3-in-aspiro-phase-1-2a-trial-highlighting-commercial-formulation-of-anpd001-and-its-transformative-potential-for-parkinsons-disease/2025-09-25T08:23:09-07:00https://aspenneuroscience.com/aspen-neuroscience-announces-115-million-series-c-financing-to-accelerate-personalized-cell-therapy-programs/2025-11-20T04:23:17-08:00https://aspenneuroscience.com/aspen-neuroscience-appoints-chief-commercial-officer-lisa-johnson-pratt-m-d-and-welcomes-revati-shreeniwas-m-d-fccp-as-chief-medical-officer-to-accelerate-late%e2%80%91stage-development-and/2026-01-07T06:28:09-08:00https://aspenneuroscience.com/aspen-neuroscience-completes-phase-1-2a-aspiro-trial-cohort-three-dosing-and-state-of-the-art-manufacturing-expansion-paving-the-way-for-developing-transformative-t/2026-07-02T11:00:53-07:00https://aspenneuroscience.com/aspen-receives-adoption-of-sasineprocel-as-the-official-nonproprietary-naming-of-anpd001-its-investigational-autologous-cell-therapy-for-the-treatment-of-parkinsons-disease/2026-07-02T11:00:21-07:00https://aspenneuroscience.com/aspen-neuroscience-announces-positive-12-month-data-from-its-aspiro-clinical-trial-in-a-late-breaking-oral-presentation-at-t/2026-07-02T11:00:02-07:00https://aspenneuroscience.com/aspen-neuroscience-appoints-jeff-boerneke-as-general-counsel-and-secretary/2026-07-02T10:59:49-07:00https://aspenneuroscience.com/aspen-neuroscience-announces-completion-of-cohort-3-and-4-dosing-in-aspiro-phase-1-2a-trial-of-sasineprocel-for-parkinsons-disease/2026-07-02T10:58:52-07:00https://aspenneuroscience.com/aspen-neuroscience-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-sasineprocel-anpd001-to-treat-parkinsons-disease/2026-07-30T06:09:05-07:00https://aspenneuroscience.com/damien-mcdevitt-ph-d/2026-09-16T18:24:40-07:00https://aspenneuroscience.com/dalen-meeter-cpa-mba/2026-09-16T18:25:41-07:00https://aspenneuroscience.com/xiaokui-zhang-ph-d/2026-10-13T19:44:25-07:00https://aspenneuroscience.com/kim-raineri-mba/2026-10-13T19:44:51-07:00https://aspenneuroscience.com/revati-shreeniwas-m-d/2026-10-07T16:30:56-07:00https://aspenneuroscience.com/ana-sousa-msj/2026-10-13T19:45:31-07:00https://aspenneuroscience.com/lisa-johnson-pratt-m-d/2026-10-19T10:52:35-07:00https://aspenneuroscience.com/jeff-boerneke-jd/2026-10-07T13:25:45-07:00https://aspenneuroscience.com/samantha-murphy-ph-d/2026-10-05T23:35:31-07:00https://aspenneuroscience.com/jennifer-whitaker/2026-10-13T19:46:04-07:00https://aspenneuroscience.com/andres-bratt-leal-ph-d/2026-10-13T19:46:28-07:00https://aspenneuroscience.com/tom-daniel-m-d/2026-10-07T16:32:30-07:00https://aspenneuroscience.com/doug-fisher-m-d/2026-10-07T13:29:42-07:00https://aspenneuroscience.com/faheem-hasnain/2026-10-07T16:35:25-07:00https://aspenneuroscience.com/damien-mcdevitt-ph-d-2/2026-09-17T10:06:17-07:00https://aspenneuroscience.com/cindy-perettie/2026-10-07T13:32:38-07:00https://aspenneuroscience.com/caryn-peterson/2026-10-07T16:28:46-07:00https://aspenneuroscience.com/drew-spaventa/2026-10-09T09:47:25-07:00https://aspenneuroscience.com/peter-thompson-m-d/2026-10-05T23:43:10-07:00https://aspenneuroscience.com/fraint-et-al-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurological-disorders-ad-pd-12-month-clinical-data-abstract/2026-09-23T13:38:29-07:00https://aspenneuroscience.com/fraint-et-al-2025-international-association-of-parkinsonism-and-related-disorders-iaprd-world-congress-6-month-clinical-data-abstract/2026-10-15T14:35:37-07:00https://aspenneuroscience.com/emborg-et-al-2024-journal-of-neurosurgery/2026-09-23T13:37:55-07:00https://aspenneuroscience.com/hills-et-al-2023-stem-cells-and-development/2026-09-23T13:38:07-07:00https://aspenneuroscience.com/bratt-leal-et-al-2026-cell-stem-cell/2026-10-05T23:43:38-07:00https://aspenneuroscience.com/ansari-et-al-2025-international-society-for-cell-gene-therapy-isct-poster/2026-09-23T14:01:15-07:00https://aspenneuroscience.com/fremgen-et-al-2025-international-society-for-stem-cell-research-isscr-poster/2026-09-23T13:58:43-07:00